Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
March 28, 2024 08:05 ET
|
Candel Therapeutics
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in...
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
March 05, 2024 16:30 ET
|
Candel Therapeutics
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
February 13, 2024 07:30 ET
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
February 05, 2024 08:00 ET
|
Candel Therapeutics
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
December 12, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
November 28, 2023 09:00 ET
|
Candel Therapeutics
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic...
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 09, 2023 08:00 ET
|
Candel Therapeutics
Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive of an increased tail on the maturing survival curveInitial data...
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
November 04, 2023 08:00 ET
|
Candel Therapeutics
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillanceApplication of the...
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
November 03, 2023 12:00 ET
|
Candel Therapeutics
Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall...
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
October 18, 2023 11:00 ET
|
Candel Therapeutics
CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeuticIn a first-in-human clinical trial...